## Supplementary data




***Supplementary Fig. S1:*** *(A) Change in cytokine and chemokine gene expression in the spleens of mice 14 days after tumour inoculation compared to untreated mice and (B) expression of macrophage surface markers in the same samples. (C-E) Recruitment of monocytes and/or neutrophils is not necessary for mAb-mediated clearance of target B cells. (C) Adoptive transfer as in Figure 1A in CCR2KO mice that exhibit a defect in monocyte recruitment to tissues, compared to in WT C57BL/6 mice, (D) Adoptive transfer with WT C57BL/6 mice vs mice treated with neutrophil depleting antibody anti-Ly6G 1A8 (500µg administered intraperitoneally 48 hours prior to adoptive transfer) and (E) Adoptive transfer in WT vs CCR2KO mice in the presence or absence of 1A8.*




***Supplementary Fig. S2:*** *Phagocytosis of hCD20 Tg murine splenic B cells by mBMDM stimulated with STINGa. Dot plots of mBMDM stimulated with LPS/IFN-γ, IL-4/-13, murine STINGa (DMXAA) or human STINGa (2'2'-, 2'3'- and 3'3'- cGAMP) overnight and co-cultured with target hCD20 Tg murine splenic B cells. Target cells were CFSE labelled before opsonising with Ritm2a and mBMDM labelled with F4/80 APC to distinguish phagocytic $CFSE^{+}APC^{+}$ macrophages (n=4-5, representative shown).*




***Supplementary Fig. S3:*** *Phenotypic changes of hMDM stimulated with TLRa. hMDM stimulated with LPS/IFN-γ (L/γ), IL-4/-13 (4/13) or TLRa were assessed for changes in expression of cell surface markers CD40, CD80, CD14, MHCII, CD206 and CD11b by flow cytometry and fold change in expression shown in relation to untreated (NT) macrophages. Data analysed by Wilcoxon signed rank test, compared to NT hMDM.*




***Supplementary Fig. S4:*** *FcγR expression and phagocytosis of CLL cells following stimulation of hMDM with TLRa or STINGa. (A) Fold change in expression levels of FcγR on hMDM stimulated with LPS/IFN-γ (L/γ), IL-4/-13 (4/13), TLRa or STINGa for 48 hours, shown in relation to non-treated (NT) macrophages normalised to 1. Each data point represents an independent experiment. Data analysed by Wilcoxon signed rank test, p values compare to NT hMDM. (B) Representative dot plots showing percentage of phagocytic macrophage stimulated with TLRa or (C) STINGa, when cocultured with CFSE labelled CLL cells opsonised with Rituximab.*




***Supplementary Fig. S5:*** *Change in chemokine and cytokine gene expression in the spleens of $BCL_1$ tumour-bearing mice treated with STING agonist DMXAA compared to untreated $BCL_1$–bearing mice. BALB/c mice were inoculated with $1x10^4$ $BCL_1$ tumour cells on day 0, treated with DMXAA on day 6 and 13, and spleen harvested on day 14. RNA was purified from spleen and cDNA synthesized. Gene expression was quantitated by real time PCR and fold change in cytokines and chemokines assessed (n=3 in each group).*